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DNA Topoisomerase II inhibitors are a type of anticancer drugs. These drugs perform their biological 
activity either by forming a DNA-intercalator-topoisomerase II ternary complex  
or by inhibiting other enzymes and/or transcription factors that act on DNA. The strong interactions with 
DNA play a crucial role for their pharmacological properties. Lunacridine, the  
active principle fromÂ  Lunasia amara,Â  was known as DNA intercalating Topoisomerase II inhibitor. 
With the aims to explore the affinity and molecular interaction of lunacridine  
compound isolated fromÂ  Lunasia amara with DNA, molecular docking study has been carried out with 
DNA model using Autodock 4.0 software. Cytotoxicity test on P388 murine leukemia cells was done also 
using 100, 30, 10, 3 and 1Â  Î¼g/ml series of lunacridine concentration. The docking result shows that 
Lunacridine itself could to dock intercalatively between base pairs of DNA and the possibility interaction 
with adenine, thymine and cytosine by dipole-dipole  
interaction.Â  The lowest predicted binding energy of lunacridine is â€“6,22 kcal/mol, whereas original 
ligand bis thiazole is -16,37 kcal/mol.Â  Lunacridine compound itself has less cytotoxic  
activity on P388 murine leukemia cells with the IC50 value of 39,52Â  Î¼g/ml or 129,41Â  Î¼M. The 
binding energy of lunacridine on DNA higher than original ligand show that the interaction of  
lunacridine with DNA is not stable afford theÂ  less cytotoxic activity. However, based on the IC50 value, 
lunacridine could be depeloved as anticancer. 
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